CN103919225B - 一种具有改善糖、脂代谢的天然植物饮料及其制备方法 - Google Patents
一种具有改善糖、脂代谢的天然植物饮料及其制备方法 Download PDFInfo
- Publication number
- CN103919225B CN103919225B CN201410181146.0A CN201410181146A CN103919225B CN 103919225 B CN103919225 B CN 103919225B CN 201410181146 A CN201410181146 A CN 201410181146A CN 103919225 B CN103919225 B CN 103919225B
- Authority
- CN
- China
- Prior art keywords
- extract
- ginkgo nut
- ginkgo
- preparation
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 235000013361 beverage Nutrition 0.000 title claims abstract description 37
- 230000004060 metabolic process Effects 0.000 title claims abstract description 9
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 62
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 62
- 241000196324 Embryophyta Species 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 241000218628 Ginkgo Species 0.000 claims abstract 17
- 239000012528 membrane Substances 0.000 claims description 44
- 239000000706 filtrate Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 claims description 28
- 244000241838 Lycium barbarum Species 0.000 claims description 25
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 25
- 238000001816 cooling Methods 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 22
- 238000003828 vacuum filtration Methods 0.000 claims description 22
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 17
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 17
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 17
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 17
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 17
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 17
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 17
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 17
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 17
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 17
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 235000015468 Lycium chinense Nutrition 0.000 claims description 11
- 241000202807 Glycyrrhiza Species 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 7
- 235000020717 hawthorn extract Nutrition 0.000 claims description 7
- 229940010454 licorice Drugs 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 238000005202 decontamination Methods 0.000 claims description 4
- 230000003588 decontaminative effect Effects 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 241001092040 Crataegus Species 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 37
- 210000004072 lung Anatomy 0.000 abstract description 23
- 235000013305 food Nutrition 0.000 abstract description 12
- 239000003963 antioxidant agent Substances 0.000 abstract description 10
- 235000006708 antioxidants Nutrition 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 10
- 230000003712 anti-aging effect Effects 0.000 abstract description 9
- 230000003078 antioxidant effect Effects 0.000 abstract description 9
- 210000002216 heart Anatomy 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 7
- 230000007812 deficiency Effects 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 5
- 210000004556 brain Anatomy 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000012423 maintenance Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000013403 hyperactivity Diseases 0.000 abstract description 2
- 244000194101 Ginkgo biloba Species 0.000 description 49
- 239000008280 blood Substances 0.000 description 43
- 210000004369 blood Anatomy 0.000 description 41
- 210000004185 liver Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 24
- 238000001914 filtration Methods 0.000 description 20
- 210000004379 membrane Anatomy 0.000 description 20
- 235000009508 confectionery Nutrition 0.000 description 17
- 235000019197 fats Nutrition 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 13
- 240000000171 Crataegus monogyna Species 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 108010023302 HDL Cholesterol Proteins 0.000 description 11
- 241000220225 Malus Species 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 240000005528 Arctium lappa Species 0.000 description 5
- 235000003130 Arctium lappa Nutrition 0.000 description 5
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 5
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 4
- 244000131316 Panax pseudoginseng Species 0.000 description 4
- 241001165494 Rhodiola Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 240000005250 Chrysanthemum indicum Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 235000008706 Ilex latifolia Nutrition 0.000 description 3
- 244000078118 Ilex latifolia Species 0.000 description 3
- 241000234435 Lilium Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- 240000007164 Salvia officinalis Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 235000021018 plums Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000005412 red sage Nutrition 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000010016 myocardial function Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- XACHQDDXHDTRLX-GMPBGBGESA-N Physalien Natural products O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)=C(C)C1)CCCCCCCCCCCCCCC XACHQDDXHDTRLX-GMPBGBGESA-N 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 240000005166 Polygonatum biflorum Species 0.000 description 1
- 235000004506 Polygonatum multiflorum Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000006688 Telosma cordata Species 0.000 description 1
- 235000017352 Telosma cordata Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- -1 carrotene Natural products 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229930184989 physalin Natural products 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N zeaxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-QAYBQHTQSA-N 0.000 description 1
- XACHQDDXHDTRLX-HZXCUAKRSA-N zeaxanthin dipalmitate Chemical compound CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC1(C)C XACHQDDXHDTRLX-HZXCUAKRSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于食品饮料技术领域,公开了一种具有改善糖、脂代谢的天然植物饮料及其制备方法。本发明一方面通过特定的提取方法,在保证有效提取银杏果中有效成分的前提下,有效清除了银杏果中的有毒成分。另一方面又根据中医理论,用玉竹等一系列可使银杏果减毒增效的天然植物与银杏果相配伍,有效增强了银杏果的保健作用,尤其适用于肺肾亏虚、肝旺脾虚、阴液亏耗以及“三高”人群,具有改善脂肪代谢、抗氧化、保护心、脑、肺等靶器官、抗衰老、养颜美容之功效。
Description
技术领域
本发明涉及食品饮料技术领域,具体涉及一种具有改善糖、脂代谢的天然植物饮料及其制备方法。
背景技术
随着社会高科技、智能化、自动化时代的发展,大幅度降低了人类体力的支出,加之生活水平的提高,热量的大量摄入,导致肥胖人数激增,过度的脂肪堆积给人们生活带来诸多不便,同时也危害人们的身心健康,易引发多种疾病,尤其是“三高”人群的数量越来越多,心脑血管发病率不断升高,高血脂对于心脑血管的危害越来越引起人们的重视。
银杏果含有丰富的维生素C、核黄素、胡萝卜素等,具有抗氧化及细胞保护作用,可延缓细胞的衰老。同时,银杏果含有的抗血小板活化因子,可以防止血液凝集、改善血液循环,防止血栓的形成,含有的黄酮则能扩张血管,清除自由基,提高人体免疫力。因此,银杏果被广泛用于延缓衰老、美容养颜和预防心脑血管疾病中。然而,银杏果本身具有心脏毒性,不宜多食,这也限制了对银杏果的进一步开发和利用。
发明内容
针对现有技术中存在的上述缺陷,本发明一方面提供了一种具有改善糖、脂代谢的天然植物饮料,其由以下原料按照以下重量份数配制而成:银杏果0.24-6.00,玉竹0.72-18.00,制乌梅0.12-3.00,枸杞0.36-9.00,山楂0.24-6.00和甘草0.36-9.00。
本发明根据中医理论,用一系列可使银杏果减毒增效的天然植物与银杏果配伍,以增强银杏果的保健作用,并且降低其毒性。
本发明所用组分及其中药药理作用如下:
1、银杏:含有丰富的维生素C、核黄素、胡萝卜素、类黄酮等,具有抗氧化、改善血液循环、扩张血管、消除自由基、保护细胞的完整性、延缓衰老的作用。
中医记载白果有镇喘止咳的功效,明代李时珍曾曰:“入肺经、益脾气、定喘咳、缩小便。”清代张璐璐的《本经逢源》中载白果有降痰、清毒、杀虫之功能,可治疗“疮疥疽瘤、乳痈溃烂、牙齿虫龋、小儿腹泻、赤白带下、慢性淋浊、遗精遗尿等症”。白果性味甘、平,微有苦、涩。具有补肾固肺、降脂、降压作用,熟食可温肺益气、降低血脂、降低血压、定喘咳、止遗尿、消白带,生食可祛痰、杀虫、解酒;汁涂擦皮肤可去皱、洁面、治疥癣螨虱。因而对防治咳喘、遗尿、白带异常、高血压、高血脂、酒精中毒,以及多种皮肤病等,都有较好的功效。银杏有着出众的抗衰老能力,其通过对血液循环的改善,防止人的血管老化、改善血管弹性,预防栓塞。也即白果能够帮助血液更顺利地通过最为细小和狭窄的血管,使大脑、心脏和四肢的组织中缺氧的部分获得营养,起到恢复记忆力和消除肌肉疼痛的效果。
2、玉竹:具有滋阴润肺、养胃生津、美容护肤的作用,并有改善心肌功能的功效。
根据中医理论,玉竹有养阴润燥,生津止渴之功效。用于肺胃阴伤,燥热咳嗽,咽干口渴,内热消渴。李时珍说:"其叶光莹像竹,其根长而多节,故有玉竹,地节诸名"。《纲目》:萎蕤,性平,味甘,柔润可食。药理证实本品具有促进实验动物抗体生成,提高巨噬细胞的吞噬百分数和吞噬指数,促进干扰素合成,抑制结核杆菌生长,降血糖,降血脂,缓解动脉粥样斑块形成,使外周血管和冠脉扩张,延长耐缺氧时间,强心,抗氧化,抗衰老等作用。还有类似腺皮质激素样作用。玉竹味甘,其能补能和能缓,可解银杏之毒,并调和药性。
3、枸杞:含胡萝卜素、硫胺素、核黄素、烟酸、抗坏血酸、β—谷甾醇、亚油酸、玉蜀黍黄素、甜菜碱、酸浆果红素及微量元素等。具有延缓衰老、降脂保肝、降低血糖、改善造血机能、增强机体免疫力的作用。
根据中医理论,枸杞味甘,性平。主要归肝、肾、肺经。其甘补平和,质润多液,入肾可益精充髓助阳;走肝能补血明目;归肺以润肺止咳。凡肝肾不足和肺肾阴虚所致诸症,均可应用。为滋阴助阳,益精补血之良药,有补肝肾,益精血,坚筋骨,壮机体久服延年益寿的功效。据文献报道枸杞子在肝脏功能正常的情况下,对肝脏的功能有促进作用,在肝脏受损的情况下对肝脏有保护作用。在肝脏再生的过程中,对其再生有促进作用。其对肝脏的保护作用可有效减少银杏的毒性。
4、山楂:具有助消化、降压、降脂、抗氧化、增强免疫力、清除胃肠道有害细菌、养肝护肝等功效。
中医认为,山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈脾满、疝气血淤闭经等症。山楂中含有山萜类及黄酮类等药物成分,具有显著的扩张血管及降压作用,有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能。一般人皆可食用。儿童、老年人、消化不良尤其适合食用。山楂与银杏同用,属药食同源草本植物精华协同作用,能防止血小板聚集,防止动脉粥样斑块沉积,降低血粘度,软化润滑血管,恢复血管弹性,是国际流行的改善血液循环组合配方;能同时降低血脂,血糖和血压,防止糖尿病,高血脂并发症;强化心肌功能,显著提高大脑血流量,全面保护心脑肾器官,特别适合中老年人服用。
5、乌梅:具有生津去火、健脾和胃、补养肝肾、增强免疫力之功效。
乌梅中含儿茶酸能促进肠蠕动,因此便秘之人宜食之。梅子中含多种有机酸,有改善肝脏机能的作用,故肝病患者宜食之。梅子中的梅酸可软化血管,推迟血管硬化,具有防老抗衰作用。乌梅是药食同源的制品,是青梅经过加工后的中药材之一,其性温,味酸涩。
与银杏配伍可增强疗效减少毒性。
6、甘草:具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药的作用。
本本发明的配方中,银杏补肺固肾是为君;玉竹养阴润燥,生津止渴加强银杏的功效而为臣;乌梅、山楂味酸入肝而能补肝、敛肝,并可敛其横逆之势,即补中寓泻,补肝体而制肝用而为佐药。甘草味甘培中以缓肝,甘味药又能调肝缓急,调和诸药故为使药。
中医有“酸甘化阴”之说,酸甘化阴是酸味与甘味药物配伍应用,藉以增强滋阴养血、生津补液药效的一种治法。成无己释云:“酸以收之,甘以缓之,故酸甘相合,用补阴血”。酸与甘合,不但可以加强养阴作用,而且还能化阴生津。因为酸能敛阴生津,甘能益胃滋阴,酸甘配伍,一敛一滋,则可两济其阴,促进脾胃生化阴液,即酸得甘助而生阴。同时由于某些酸、甘药具有“酸先入肝,甘先入脾”的特性,因此酸甘化阴法尤以养脾胃津液和补肝阴为其特长。
在本发明优选的实施方案中,所述原料的重量份数分别为:银杏果0.24,玉竹0.72,制乌梅0.12,枸杞0.36,山楂0.24和甘草0.36。
在本发明另一优选的实施方案中,所述原料的重量份数分别为:银杏果6.0,玉竹18.0,制乌梅3.0,枸杞9.0,山楂6.0和甘草9.0。
在本发明更加优选的实施方案中,所述原料的重量份数分别为:银杏果1.2,玉竹3.6,制乌梅0.6,枸杞1.8,山楂1.2和甘草1.8。
本发明银杏果的减毒增效作用还可通过与以下天然植物相配伍而实现:
1、百合:甘,寒,归心、肺经。养阴润肺,清心安神。用于阴虚燥咳,劳嗽咳血,虚烦惊悸,失眠多梦,精神恍惚。百合除含有蛋白质21.29%、脂肪12.43%、还原糖11.47%、淀粉1.61%,及钙、磷、铁、每百克含1.443毫克维生素B、21.2毫克维生素C等营养素外,还含有一些特殊的营养成分,如秋水仙碱等多种生物碱。这些成分综合作用于人体,不仅具有良好的营养滋补之功,而且还对秋季气候干燥而引起的多种季节性疾病有一定的防治作用。中医上讲鲜百合具有养心安神,润肺止咳的功效。
2、菊花:甘、苦,微寒。归肺、肝经。散风清热,平肝明目,清热解毒。用于风热感冒,头痛晕眩,目赤肿痛,眼目昏花,疮痈肿痛。现代药理研究表明,菊花具有治疗冠心病、降低血压、预防高血脂、抗菌、抗病毒、抗炎、抗衰老等多种药理活性。
3、丹参:苦,微寒。归心、肝经。活血祛瘀,痛经止痛,清心除烦,凉血消痈,用于胸痹心痛,脘腹胁痛,癓瘕积聚,热痹疼痛,心烦不眠,月经不调,痛经经闭,疮痈肿痛。丹参主要用于心血管疾病的治疗,对冠心病、高血压、高血脂有非常好的疗效,对糖尿病也有一定的治疗效果。丹参能扩张冠状动脉,增加冠脉流量,改善心肌缺血、梗塞和心脏功能,调节心律,并能扩张外周血管,改善微循环;能提高机体耐缺氧能力;有抗凝血,促进纤溶,抑制血小板凝聚,抑制血栓形成的作用;能降低血脂,抑制冠脉粥样硬化形成;能抑制或减轻肝细胞变性、坏死及炎症反应,促进肝细胞再生,并有抗纤维化作用。
4、苦丁茶:苦,凉。归肝、肺、胃经。疏风清热,活血。用于头痛,目赤口苦,鼻炎,中耳炎。苦丁茶的药用效果非常明显,中医认为,它具有散风热、清头目、除烦渴的作用,可用来治疗头痛、牙痛、目赤、热病烦渴、痢疾等。现代药理研究则证明,苦丁茶中不仅含有人体必需的多种氨基酸、维生素及锌、锰、铷等微量元素,还具有降血脂、增加冠状动脉血流量、增加心肌供血、抗动脉粥样硬化等作用,对心脑血管疾病患者的头晕、头痛、胸闷、乏力、失眠等症状均有较好的防治作用,因此备受中老年人的青睐。
5:绞股蓝:为多年生宿根植物,性寒、味甘,有益气,安神,降血压之功效
经现代医学研究发现,绞股蓝主要有效成分为多糖类、黄酮类、皂苷类及微量元素类,其功效主要是促进人体脂肪类物质代谢、营养人体细胞,并有解毒消炎作用。
经过药理,毒理及临床证明,绞股蓝具有“适应源”样功能,对多种癌细胞有显著的抑制作用;此外,绞股蓝还有降血脂、降血压、降血糖、镇静、催眠、抗紧张、抗溃疡、抗疲劳、增强抵抗力,平喘止咳,等多种功效。另外绞股蓝还具有清脂、排毒、消炎、修复药物对人体器官的损伤、滋养人体细胞、营养肝脏等肝器,恢复人体器官活力的作用。适用于高血压患者,高血糖患者,高血脂患者,肝胆炎症患者,睡眠不好者,肥胖者,心脑血管患者,内分泌失调者,长期处于疲劳状态者,亚健康者等人群。
6、三七:又名田七,甘、微苦、温。归肝、胃经。散瘀止血,消肿定痛。用于咯血,吐血,衄血,便血,崩漏,外伤出血,胸腹刺痛,跌扑肿痛。
中医认为:“百病皆有淤”,“血不运则百病生”。气血只有保持流畅,才能达到动态平衡;如果气血运行失调,失去平衡,则能影响到脏腑、经络、阴阳等各方面功能的协调平衡,出现五脏六腑、表里内外、四肢九窍等各方面病变,促人衰老。
三七富含三七皂苷、三七多糖、三七素、黄酮有效成分,具有止血、活血化瘀、消肿定痛、滋补强壮、抗疲劳、耐缺氧、抗衰老、降血脂、降血糖、提高机体免疫功能等作用。
现代研究表明,三七具有多种保健功能:
(1)扩张血管、降低血压,改善微循环,增加血流量,预防和治疗心脑组织缺血、缺氧症;
(2)促进蛋白质、核糖核酸(RNA)、脱氧核糖核酸(DNA)合成,强身健体;
(3)促进血液细胞新陈代谢,平衡调节血液细胞;
(4)双向调节中枢神经,提高脑力,增强学习和记忆能力;
(5)增强机体免疫功能,抗肿瘤;
(6)止血、活血化瘀;
(7)保肝、抗炎;
(8)延缓衰老;
(9)双向调节血糖、降低血脂、胆固醇、抑制动脉硬化。
7、红景天:为景天科植物大花红景天,甘、苦,平。归肺、心经。益气活血,通脉平喘。用于气虚血瘀,胸痹心痛,中风偏瘫,倦怠气喘。
现代研究证明,红景天的适应原样作用,能提升机体对有害刺激的非特异性抵抗力,加强肌体的适应性。透过增强体内细胞的氧气扩散,或氧气运用效益、抗氧化的能力,有助提高身体对缺氧刺激的适应力。
红景天广泛用于改善睡眠、生血活血、抗脑缺氧、抗疲劳、活血止血、清肺止咳、化淤消肿、解热退烧、滋补元气等功效。
8、牛蒡子:为菊科植物牛蒡的干燥成熟果实,辛、苦,寒。归肺、胃经。疏散风热,宣肺透疹,解毒利咽。用于风热感冒,咳嗽痰多,麻疹,风疹,咽喉肿痛,痄腮,丹毒,痈肿疮毒。
牛蒡子属于解表药中发散风热药,常与地丁,野菊花等清热解毒药配伍。现代研究,牛蒡子还可用于防治糖尿病肾病;牛蒡果实含牛蒡甙经水解生成的牛蒡甙元具有抗癌活性。
本发明的另一方面提供了制备本发明的植物饮料的方法,包括如下步骤:
1、银杏果提取物、玉竹提取物、制乌梅提取物、枸杞提取物、山楂提取物和甘草提取物的制备;
2、将制备得到的各提取物进行混合,加水至规定量,并搅拌均匀;
3、将配制好的溶液过滤,经分装密封后加热灭菌;
其中银杏果提取物的制备包括预处理、水提、去杂质和检测滤液中银杏酚酸含量等步骤。
在本发明优选的实施方案中,银杏果的预处理步骤包括将银杏种仁挑选剔除不良品后去衣,并剖开去除胚。
在本发明优选的实施方案中,银杏果的水提步骤为称取规定量的处理好的种仁,分别加水10倍、8倍和5倍,加热至摄氏100度-132度之间,提取1-30分钟,提取三次,合并每次获得的滤液。
在本发明优选的实施方案中,银杏果的沉淀去杂质步骤为合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣留取滤液。
在本发明优选的实施方案中,银杏果的检测滤液中银杏酚酸含量的步骤保证银杏果提取物中检测不出银杏酸。
在本发明优选的实施方案中,玉竹提取物、制乌梅提取物、枸杞提取物、山楂提取物和甘草提取物的制备步骤分别为称取规定量的玉竹、制乌梅、枸杞、山楂和甘草,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
综上所述,本发明制备的植物饮料,一方面通过特定的提取方法,在保证有效提取银杏果中有效成分的前提下,有效清除了银杏果中的有毒成分。另一方面又根据中医理论,用一系列可使银杏果减毒增效的天然植物与银杏果相配伍,有效增强了银杏果的保健作用,尤其适用于肺肾亏虚、肝旺脾虚、阴液亏耗以及“三高”人群,具有改善脂肪代谢、抗氧化、保护心、脑、肺等靶器官、抗衰老、养颜美容之功效。
附图说明
图1:处理1分钟和30分钟后本发明A、B、C饮料组与空白对照组抗氧化、抗衰老试验对照图。
CK1:对照组处理1分钟;
A1:A组处理1分钟;
B1:B组处理1分钟;
C1:C组处理1分钟;
CK2:对照组处理30分钟;
A2:A组处理:30分钟;
B2:B组处理:30分钟;
C2:C组处理:30分钟。
具体实施方式
下面通过实施例对本发明作进一步的详细说明,旨在用于说明本发明而非限定本发明。应当指出,对于本领域技术人员而言,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也同样落入本发明的保护范围之内。
实施例1天然植物饮料的制备(最低限配方)
1、银杏果提取物的制备
将银杏种仁挑选剔除不良品后去衣,剖开去除胚,称取24克处理好的种仁,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣留取滤液,检测滤液中银杏酚酸含量后备用。
本发明通过检测控制银杏提取液中银杏酚酸的总量来保证饮料的安全性,银杏酚酸的主要组分有5种,即C13:0、C15:1、C17:2、C15:0和C17:1。
采用如下的方法对银杏酚酸进行检测:
(1)色谱条件与系统适用性实验
用十八烷基硅烷键合硅胶为填充剂,甲醇-1%冰醋酸溶液(90:10)为流动相,检测波长为310nm,柱温35℃,理论板数按银杏酸C13:0峰计算应不低于4000。
(2)对照品溶液的制备
精密称取银杏酸C13:0对照适量,加甲醇-水(甲醇:水=1:1)制成每1ml含5ug的溶液,作为对照品溶液,另取总银杏酸对照品适量加甲醇-水(甲醇:水=1:1)制成每1ml含100ug的溶液,作为定位用对照溶液。
(3)供试品溶液的制备
精密量取银杏提取液25ml置于50ml容量瓶中,加入甲醇制成50ml的供试品溶液。
(4)测定方法
精密吸取供试品溶液、对照品溶液及定位对照品溶液各10ul注入液相色谱仪,计算供试品溶液中与总银杏酸对照品相应色谱峰面积,供试品溶液中不得含有总银杏酸对照品相应色谱峰,即供试品不得检测出银杏酸。
2、玉竹提取物的制备
称取72克玉竹,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
3、制乌梅提取物的制备
称取12克制乌梅,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
4、枸杞提取物的制备
称取36克枸杞,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
5、山楂提取物的制备
称取24克山楂,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
6、甘草提取物的制备
称取36克甘草,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
7、饮料的配制
将得到的银杏、山楂、甘草、制乌梅、玉竹、枸杞提取物滤液混合,加纯水至100升,并搅拌均匀。
将配制好的滤液,经分装密封后加热至摄氏100度灭菌30分钟。
实施例2天然植物饮料的制备(最优配方)
1、银杏果提取物的制备
将银杏种仁挑选剔除不良品后去衣,剖开去除胚,称取120克处理好的种仁,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣留取滤液,检测滤液中银杏酚酸含量后备用。
采用与实施例1相同的方法对银杏酚酸进行检测。
2、玉竹提取物的制备
称取360克玉竹,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
3、制乌梅提取物的制备
称取60克制乌梅,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
4、枸杞提取物的制备
称取180克枸杞,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
5、山楂提取物的制备
称取120克山楂,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
6、甘草提取物的制备
称取180克甘草,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
7、饮料的配制
将得到的银杏、山楂、甘草、制乌梅、玉竹、枸杞提取物滤液混合,加纯水至100升,并搅拌均匀。
将配制好的滤液,经分装密封后加热至摄氏100度灭菌30分钟。
实施例3天然植物饮料的制备(最高限配方)
1、银杏果提取物的制备
将银杏种仁挑选剔除不良品后去衣,剖开去除胚,称取600克处理好的种仁,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣留取滤液,检测滤液中银杏酚酸含量后备用。
采用与实施例1相同的方法对银杏酚酸进行检测。
2、玉竹提取物的制备
称取1800克玉竹,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
3、制乌梅提取物的制备
称取300克制乌梅,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
4、枸杞提取物的制备
称取900克枸杞,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
5、山楂提取物的制备
称取600克山楂,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
6、甘草提取物的制备
称取900克甘草,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜两次过滤(真空抽滤),除去滤渣备用。
7、饮料的配制
将得到的银杏、山楂、甘草、制乌梅、玉竹、枸杞提取物滤液混合,加热至摄氏60度,真空减压(真空度为0.095MPa)浓缩至十分之一体积的浓浆,经分装密封后加热至摄氏100度30灭菌分钟备用。配置饮料时,加纯水至100升,搅拌均匀即可。
将配制好的滤液,经分装密封后加热至摄氏100度灭菌30分钟。
实施例4降血脂试验
1、供试动物
SPF级雄性SD大鼠50只,180~220g,高脂饲料及基础饲料粉。饲养于SPF级设施。室温22±2℃,相对湿度60%-70%。
2、受试品
按照实施例1-3所生产的上述饮料A(最低限配方),B(最高限配方),C(最优配方)。
3、高脂营养饲料配方及制备
77.8%基础饲料粉,2%胆固醇,10%蛋黄粉和10%猪油,0.2%胆酸钠制成颗粒状,于80℃烘箱内烤干。
4、仪器和试剂
OLYMPUS CH30显微镜,日本OLYMPUS生产;LEICA RM2245型切片机,德国LEICA公司生产;TC(总胆固醇)、TG(甘油三酯)、HDL-C(高密度脂蛋白胆固醇)项目用日立7600全自动生化仪检测,检测试剂盒均由中生北控生物科技股份有限公司提供。
5、试验方法
将40只大鼠饲喂基础饲料观察5d,禁食16h,眼眶静脉丛采血,测定血清TC、TG、HDL-C水平,然后开始饲喂高脂饲料,3周后,眼眶静脉丛采血,测定血清TC、TG、HDL-C水平,与饲喂高脂饲料前比较,确定已形成高脂血症模型后,根据TC水平将40只大鼠随机平均分为一个高脂模型组和A、B、C三个配方组。高脂模型组继续饲喂高脂饲料,各配方组继续饲喂高脂饲料的同时分别以A、B、C三个配方灌服饮料15ml/kg,另设空白对照组饲喂基础饲料,35d后,将所有大鼠禁食16h,眼眶静脉丛采血,测定各组血清TC、TG、HDL-C水平,然后同时处死所有大鼠取其心、肝、脾、肺、肾,用10%的中性福尔马林固定,做常规组织切片,HE染色。
6、统计分析
采用SPSS13.0统计软件进行分析。所有计量资料采用均数±标准差表示。计量资料样本间比较
采用t检验和单因素方差分析(one-way ANOVA)。以P<0.05为差异有统计学意义。
7、试验结果
(1)高脂血症大鼠模型的建立
40只大鼠给予高脂饲料3周后,TC、TG、HDL-C水平显著升高(具体实验数据参见表1)。
表1高脂饲料饲喂前后TC、TG、HDL-C水平的比较
组别 | TC/mmol·L-1 | TG/mmol·L-1 | HDL-C/mmol·L-1 |
高脂饲料饲喂前 | 1.55±0.21 | 0.77±0.23 | 0.86±1.54 |
高脂饲料饲喂后 | 5.14±1.58 | 1.26±0.51 | 1.36±0.31 |
(2)灌服饮料后血清TC、TG、HDL-C水平比较
A、B、C组血清TC、TG、HDL-C水平低于高脂模型组,但高于普通对照组,并且C<B<A(具体实验数据参见表2)。此外,高脂模型组肝脏结构模糊,肝细胞索排列紊乱,肝细胞弥漫性脂肪变性,肝细胞的胞浆内出现大小不等的脂滴;灌服饮料各组肝脏病变比高脂模型组有所减轻,肝细胞索排列整齐,病变波及范围明显缩小,肝细胞的胞浆内脂滴体积变小,而且C表现最好,B次之。各剂量组其余器官组织学检验无异常。
表2各组TC、TG、HDL-C水平比较
实施例5抗氧化、抗衰老试验
1、试验目的
越来越多的研究显示抗氧化是预防衰老的原因,因为自由基或氧化剂会将细胞和组织分解,影响代谢功能,并会引起不同的健康问题。而每天的生活中,有太多会加速肌肤细胞氧化的可怕杀手,如手机、电磁波、紫外线、空气污染、油炸食物及压力等。如果能够消除过多的氧化自由基,对于许多自由基引起的及老化相关疾病都能够预防。
2、试验材料
实施例1-3生产的饮料A(最低限配方),B(最高限配方),C(最优配方),苹果1个,刀子1把。
3、试验步骤
(1)切4块同等大小的苹果;
(2)在4块苹果的表面用刀子划几条纵横线,增加与氧气的接触面积;
(3)试验组苹果分别喷上等量A、B、C饮料,对照组苹果不喷,观察氧化情况;
(4)分别在1分钟、3分钟、5分钟、20分钟、30分钟后,在试验组苹果喷上等量A、B、C饮料,观察试验组与对照组苹果的氧化情况并记录结果。
4、试验结果
不到1分钟,没喷饮料的对照组苹果已经被氧化成黄色。30分钟内喷了A、B、C饮料的试验组苹果几乎没有发生变化,与越来越黄的对照组苹果形成鲜明的对比,具体氧化对比情况参见附图1。
5、试验结论
本申请所制备的饮料有良好的抗氧化作用。因此,摄取足够的抗氧化剂后,不但可防止肌肤衰老,还可以延缓身体细胞的退化速度。
实施例6化痰清肺试验
1、供试动物
昆明种小鼠,普通级。
2、试验试剂
实施例1-3制备的饮料A(最低限配方),B(最高限配方),C(最优配方)。
3、试验仪器
离心机,可见光分光光度计。
4、试验方法
取小鼠60只,体质量(25±2)g,雌雄兼用。随机分成5组,每组12只,连续灌胃(ig)给药3d,每天1次,饮料A(最低限配方),B(最高限配方),C(最优配方)15ml/kg,空白对照组给予等容积的生理盐水(15ml/kg),阳性组给予盐酸氨溴索(0.06g/kg),末次灌胃前禁食不禁水12h,灌胃30min后ip注射0.5酚红溶液0.5mL,15min后处死小鼠,仰位固定于蛙板上,解部分离气管,用滤纸吸进其周围的血液,气管插管从甲状软骨处插入8号针头0.5cm,用备好的线结扎固定。用1mL注射器吸取5%NaHCO3溶液0.5mL,注入气管内,反复连续推抽3次灌洗呼吸道,洗出液收集在试管中,按上述方法重复3次,共冲洗9次,合并洗出液约1.2~1.5mL,离心(3000r/min)10min,取上清液,用723型分光光度计比色(波长546nm),用5%NaHCO3溶液调“0”,通过测定已知酚红溶液不同的浓度(标准曲线),将测得标准曲线结果保存于分光光度计中,输入样品直接计算酚红浓度(μg/mL),具体实验数据参见表3。
表3本发明各饮料组对小鼠气管段酚红排泌量的影响(n=12)
5、试验结果
表3的结果显示,饮料A(最低限配方),B(最高限配方),C(最优配方)组及阳性对照组均能明显增加小鼠呼吸道黏膜酚红排泌量,与空白对照组比较,均有显著性差异(P<0.01)。试验结果表明本发明所制备的饮料具有明显的祛痰清肺作用。
实施例7使用效果实例
房某,男,52岁,常年抽烟喝酒导致喉咙干涩痰多,体感疲惫无精神。连续饮用本品,每天早晚各一瓶,2周后喉咙不适得到较大缓解,痰多现象明显减少;每晚睡眠质量也有较大提高,白天精神状态好很多。喝完酒后马上喝本品,晕乎乎的状态也得到改善。
王某某,女,42岁,外企副总,工作量多时间长,压力大,还需经常国内外出差,导致面色灰暗,皮肤干燥,还经常失眠。经每天2~3瓶饮用本品3周后,面色改善,皮肤变光泽,睡眠质量提高,人也显得年轻。
李某,男,43岁,公司市场部经理,常年在外应酬喝酒,身体发福,体重超标,血脂、血压、血糖均偏高。每天早晚各一瓶连续饮用本品,3个月后,血脂显著下降,血压、血糖均有所改善,人也比以前精神,体重有所下降。
Claims (10)
1.一种具有改善糖、脂代谢的天然植物饮料,其由以下原料按照以下重量份数配制而成:
银杏果0.24-6.00,玉竹0.72-18.00,制乌梅0.12-3.00,枸杞0.36-9.00,山楂0.24-6.00和甘草0.36-9.00。
2.根据权利要求1所述的植物饮料,其中所述原料的重量份数分别为:
银杏果0.24,玉竹0.72,制乌梅0.12,枸杞0.36,山楂0.24和甘草0.36。
3.根据权利要求1所述的植物饮料,其中所述原料的重量份数分别为:
银杏果1.2,玉竹3.6,制乌梅0.6,枸杞1.8,山楂1.2和甘草1.8。
4.根据权利要求1所述的植物饮料,其中所述原料的重量份数分别为:
银杏果6.0,玉竹18.0,制乌梅3.0,枸杞9.0,山楂6.0和甘草9.0。
5.制备权利要求1-4中任一项所述的植物饮料的方法,包括如下步骤:
(1)银杏果提取物、玉竹提取物、制乌梅提取物、枸杞提取物、山楂提取物和甘草提取物的制备;
(2)将制备得到的各提取物进行混合,加水至规定量,并搅拌均匀;
(3)将配制好的溶液过滤,经分装密封后加热灭菌;
其中银杏果提取物的制备包括预处理、水提、去杂质和检测滤液中银杏酚酸含量的步骤。
6.根据权利要求5所述的方法,其中银杏果的预处理步骤包括将银杏种仁挑选剔除不良品后去衣,并剖开去除胚。
7.根据权利要求5所述的方法,其中银杏果的水提步骤为称取规定量的处理好的种仁,分别加水10倍、8倍和5倍,加热至摄氏100度-132度之间,提取1-30分钟,提取三次,合并每次获得的滤液。
8.根据权利要求5所述的方法,其中银杏果的沉淀去杂质步骤为合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜真空抽滤两次,除去滤渣留取滤液。
9.根据权利要求5所述的方法,其中银杏果的检测滤液中银杏酚酸含量的步骤保证银杏果提取物中检测不出银杏酸。
10.根据权利要求5所述的方法,其中玉竹提取物、制乌梅提取物、枸杞提取物、山楂提取物和甘草提取物的制备步骤分别为称取规定量的玉竹、制乌梅、枸杞、山楂和甘草,分别加水10倍、8倍和5倍,加热至摄氏100度,搅拌提取20分钟,提取三次,合并每次获得的滤液,冷却后用200目滤膜初滤,再用500目滤膜真空抽滤两次,除去滤渣备用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410181146.0A CN103919225B (zh) | 2014-04-30 | 2014-04-30 | 一种具有改善糖、脂代谢的天然植物饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410181146.0A CN103919225B (zh) | 2014-04-30 | 2014-04-30 | 一种具有改善糖、脂代谢的天然植物饮料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103919225A CN103919225A (zh) | 2014-07-16 |
CN103919225B true CN103919225B (zh) | 2015-08-19 |
Family
ID=51137809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410181146.0A Expired - Fee Related CN103919225B (zh) | 2014-04-30 | 2014-04-30 | 一种具有改善糖、脂代谢的天然植物饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103919225B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1530033A (zh) * | 2003-03-17 | 2004-09-22 | 刘小蓉 | 嗜酒人群保健品添加剂及制品 |
CN101024038A (zh) * | 2007-03-22 | 2007-08-29 | 刘荣常 | 一种具有清血脂降血压作用的药物组合物 |
CN101455806A (zh) * | 2008-11-27 | 2009-06-17 | 朱新华 | 一种具有止咳润肺功效的药物 |
CN102948561A (zh) * | 2011-11-07 | 2013-03-06 | 沈阳创达技术交易市场有限公司 | 一种瘦身保健茶 |
-
2014
- 2014-04-30 CN CN201410181146.0A patent/CN103919225B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1530033A (zh) * | 2003-03-17 | 2004-09-22 | 刘小蓉 | 嗜酒人群保健品添加剂及制品 |
CN101024038A (zh) * | 2007-03-22 | 2007-08-29 | 刘荣常 | 一种具有清血脂降血压作用的药物组合物 |
CN101455806A (zh) * | 2008-11-27 | 2009-06-17 | 朱新华 | 一种具有止咳润肺功效的药物 |
CN102948561A (zh) * | 2011-11-07 | 2013-03-06 | 沈阳创达技术交易市场有限公司 | 一种瘦身保健茶 |
Non-Patent Citations (2)
Title |
---|
中国医学科学院劳动卫生及职业病研究所,中国医学科学院药物研究所.银杏.《野生植物的营养与毒性》.人民卫生出版社,1961, * |
殷智 等.银杏果、叶及其提取物的药理作用.《湖北民族学院学报(医学版)》.2000,第17卷(第1期), * |
Also Published As
Publication number | Publication date |
---|---|
CN103919225A (zh) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552493A (zh) | 一种解酒防醉的组合物及其制备方法 | |
CN105265672B (zh) | 一种核桃分心木茶的生产方法 | |
CN106689933A (zh) | 一种富含天然成分提取物的解酒护肝饮料及其制备方法 | |
CN106359720A (zh) | 一种清咽利喉和润肺清火的保健茶及其制备方法 | |
CN113768004A (zh) | 一种含陈皮的白茶调味茶及其制备方法 | |
CN109123301A (zh) | 一种芦笋发酵固体饮料及其制备方法和应用 | |
CN106692673A (zh) | 汉方清肺茶组合物及其制备方法 | |
CN105255637A (zh) | 一种养生酒及其酿制方法 | |
CN108813501A (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
CN105029553A (zh) | 一种果汁蛋钙中药保健饮料及其制备方法 | |
CN104225295B (zh) | 用于改善睡眠的组合物及其制备方法和应用 | |
CN111214615A (zh) | 一种治疗口臭的凉茶饮料及其制备方法与质量检测方法 | |
CN103520302B (zh) | 一种沙棘叶抗疲劳胶囊及其制备方法 | |
KR20200087606A (ko) | 기억력, 학습력 향상 및 스트레스 완화용 총명탕 조성물 | |
CN110093239A (zh) | 一种诺丽配制酒及其制备方法 | |
CN104435648A (zh) | 一种食药两用的组合物及其用途和制备方法 | |
CN108041397A (zh) | 一种提升睡眠质量的固体饮料 | |
CN108969591A (zh) | 一种净化血液的制剂 | |
CN104388263A (zh) | 山楂桂圆养生中药酒及制备方法 | |
CN103919225B (zh) | 一种具有改善糖、脂代谢的天然植物饮料及其制备方法 | |
CN101411493B (zh) | 一种防治疲劳型亚健康的凉茶及其制备方法 | |
CN108498700B (zh) | 一种治疗咳嗽的中药组合物及其制备方法 | |
CN110025011A (zh) | 一种增强免疫力的麦冬人参含片 | |
CN104383265A (zh) | 双参补气养生中药酒及制备方法 | |
CN109730312A (zh) | 酵素组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150819 Termination date: 20190430 |
|
CF01 | Termination of patent right due to non-payment of annual fee |